Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.41 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK3 | P49761 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18336768 | 0.82 | KDM4E (0.39) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL18335903 | 0.75 | MEN1 (0.36) | AADATMEN1KMT2ALMNAPOLB | |
| SCHEMBL31751270 | 0.75 | KDM4E (0.47) | MEN1KMT2ARAB9AHTTSMN1; SMN2 | |
| SCHEMBL18335769 | 0.74 | PARG (0.39) | CDK9DYRK1AMEN1KMT2ALMNA | |
| SCHEMBL31559679 | 0.74 | CSNK1E (0.43) | CDK9DYRK1ADYRK2CSNK1ECLK1 | |
| SCHEMBL18336161 | 0.70 | AADAT (0.41) | AADATMEN1KMT2APOLB | |
| SCHEMBL17678057 | 0.70 | CDK9 (0.47) | CDK9DYRK1ADYRK2CSNK1ECLK1 | |
| SCHEMBL31330522 | 0.67 | CNR1 (0.41) | CNR1CDK9DYRK1ADYRK2CSNK1E | |
| SCHEMBL12933338 | 0.67 | MEN1 (0.51) | MEN1KMT2ALMNAHTTSMN1; SMN2 | |
| SCHEMBL28662671 | 0.66 | CDK4 (0.37) | METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3683222-B1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-10-06 | — | — | EP | disclosed |
| EP-3683222-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2020-07-22 | — | — | EP | disclosed |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-09-04 | — | — | US | disclosed |
| EP-3135674-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376289-A1 | NOVEL BICYCLIC OR TRICYCLIC HETEROCYCLIC COMPOUND | CBR3, CBR1, CYCS | AADAT 3986/4885CNR1 5/4885CDK9 1972/4885 |
| US-10065972-B2 | Bicyclic or tricyclic heterocyclic compound | CBR3, CBR1, CYCS | AADAT 4071/4885CNR1 5/4885CDK9 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.